Drugs / Delta Inulin
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03945825 | Jun 2019 → Sep 2020 | influenza | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 1/21 trial · 1 missed | ||||||
| Phase 1/2 | NCT03066986 | Oct 2016 → Dec 2021 | insect Stings, hypersensitivity to | Central Adelaide Local Health Network Incorporated | Unknown | Missed primary |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Delta Inulin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03945825 ↗ |
| Modality | Other / unclassified | “delta-inulin as an adjuvant” NCT03066986 ↗ |
| Route | Intramuscular | “0.5 mL of 2018/2019 Fluzone QIV + 0.5 mL of Delta Inulin-CpG55.2 (admixed with vaccine) intramuscular injection” NCT03945825 ↗ |